Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

Neurology

Volumn 65, Issue 6, 2005, Pages 812-819

  Rog, David J ^a   Nurmikko, Turo J ^b,c   Friede, Tim ^d   Young, Carolyn A ^a,b  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Pain Research Institute   (United Kingdom)

^d LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; DRONABINOL; MUSCLE RELAXANT AGENT; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LONG TERM MEMORY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MOUTH MUCOSA; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SOMNOLENCE; VISUAL ANALOG SCALE; XEROSTOMIA;

EID: 25444530723     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000176753.45410.8b     Document Type: Article

References (35)

1. Mersky H, Bogduk N. Classification of chronic pain. Seattle: IASP Press, 1994.
2. Biovie J. Central pain. In: Wall, PD, Melzack R, eds, Textbook of pain, 4th ed. Hong Kong: Harcourt, 1999:879-914.
3. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 1991;84:197-200.
4. Thompson AJ. Symptomatic treatment in multiple sclerosis. Curr Opin Neurol 1998;11:305-309.
5. Bonica JJ. Introduction: semantic, epidemiologic, and educational issues. In: Casey, KL, eds. Pain and central nervous system disease: the central pain syndromes. New York: Raven Press, 1991:21.
6. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001;63:569-611.
7. Lyman WD, Sonett JR, Brosnan CF, Delta 9 tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 1989;23:73-81.
8. Karst M, Salim K, Burstein CI, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. A randomized controlled trial. JAMA 2003;290:1757-1762.
9. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17:21-29.
10. Campbell FA, Tramer MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323:13-16.
11. Pertwee RG. Prescribing cannabinoids for multiple sclerosis: current issues. CNS Drugs 1999;11:327-334.
12. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997;48:332-338.
13. Rog DJ, Young CA. Validation and reliability of the Neuropathic Pain Scale in multiple sclerosis. Mult Scler 2001;7:S111. Abstract.
14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability scale. Neurology 1983;33:1444-1452.
16. Rao SM. Cognitive Function Study Group. National Multiple Sclerosis Society. A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. New York: National Multiple Sclerosis Society, 1990.
17. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-370.
18. Sharrack B, Hughes RAC. Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 1999;5:223-233.
19. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. JAMA 1998;280:1837-1842.
20. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998;280:1831-1836.
21. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329:253-258.
22. Attal N, Bouhassira D. Can pain be more or less neuropathic? Pain 2004;110:510-511.
23. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. Symptoms and signs in patients with suspected neuropathic pain. Pain 2004;110:461-469.
24. Spissu A, Cannas A, Ferrigno P, Pelaghi AE, Spissu M. Anatomic correlates of painful tonic spasms in multiple sclerosis. Mov Disord 1999;14:331-335.
25. Osterman PO, Westerberg CE. Paroxysmal attacks in multiple sclerosis. Brain 1975;98:189-202.
26. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, placebo-controlled trial. Pain 2003;104:323-331.
27. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy. A randomized controlled trial. Neurology 2004;63:2104-2110.
28. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
29. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400.
30. Houtchens MK, Richert JR, Sami A, Rose JW. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler 1997;3:250-253.
31. Ramsaransing G, Zwanikken C, De Keyser J. Drug points: worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ 2000;320:1113.
32. Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurology 2002;58:1404-1437.
33. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-1526.
34. Solowij N, Stephens RS, Roffmen RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002;287:1123-1131.
35. Langdon DW, Thompson AJ, Johnson KP, et al. The psychological effects of cannabis in MS: impact on cognition, pain, mood and fatigue. Mult Scler ECTRIMS 2003;9:S27. Abstract.